Skip to content
drillr.ai
Sign up

09939.HK

Kintor Pharmaceutical Limited

HKSE · Healthcare · Biotechnology · CN

HKD 1.82
−3.70%
Ask drillr

  • Sep 6, 2026, 23:21 UTC

    Kintor Pharmaceutical announced on September 4, 2026 that its self-developed tyrosinase inhibitor KT-939 successfully completed a human long-term safety trial, with no skin adverse reactions observed in 114 subjects over 52 weeks of topical use, and the company is advancing registration with China's National Medical Products Administration.

    Source:

  • Aug 20, 2026, 01:48 UTC

    Kintor Pharmaceutical reported interim results for the six months ended June 2026, with revenue of RMB 52.04 million, up about 7.7 times year-on-year, and a narrowed net loss of RMB 75.782 million from RMB 83.268 million a year earlier.

    Source: